Skip to main content

Advertisement

Clinical Pearls

Andrew Penn
Clinical Pearls
08/08/2024
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS, PMHNP, discusses the evolving questions around ketamine for depression including redosing, financial implications, and pragmatic considerations.
Andrew Penn, MS,...
08/08/2024
Psych Congress NP Institute
Desiree Matthews
Clinical Pearls
07/19/2024
Gain insights into the considerations for initiating LAI antipsychotics and optimizing therapeutic plasma concentrations with Psych Congress NP Institute Steering Committee Member Desiree Matthews, PMHNP-BC.
Gain insights into the considerations for initiating LAI antipsychotics and optimizing therapeutic plasma concentrations with Psych Congress NP Institute Steering Committee Member Desiree Matthews, PMHNP-BC.
Gain insights into the...
07/19/2024
Psych Congress NP Institute
Brooke Kempf
Clinical Pearls
04/03/2024
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC, offers her thoughts on how to approach the nuanced decision-making process of augmenting antidepressants.
Brooke Kempf, MSN, PMHNP-BC,...
04/03/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute